On November 17, 2020, Achieve hosted a virtual roundtable discussion featuring a panel of esteemed smoking cessation thought leaders. Panelists presented results from the ORCA-1 and RAUORA trials, highlighting the efficacy and tolerability of cytisinicline as an aid to smoking cessation. Further discussion included a review of the ongoing Phase 3 “ORCA-2 Trial”, currently enrolling 750 smokers at 15 clinical sites in the U.S. The need for more smoking cessation options was reinforced by a presentation of data on the impact of COVID-19 on smoking. The roundtable concluded with a Q&A session with the expert panelists.